Celgene announces post-hoc analysis of data from Phase 3 RADIANCE Part B trial showing oral ozanimod reducing brain volume loss across age subgroups (96.47)
- Results of a post-hoc analysis of data from the Phase 3 RADIANCE Part B trial showed that ozanimod reduced cortical grey matter volume loss versus first-line treatment, Avonex (interferon beta-1a), in adults with relapsing multiple sclerosis (RMS) across all age groups, including patients ages 18 to 25. The analysis will be presented at the 2019 American Academy of Neurology Annual Meeting.
- In this post-hoc analysis of 874 patients, treatment effect on serial brain volume, including thalamic volume and cortical grey matter, was evaluated by patient age (18 to 25, n=146; 26 to 34, n=265; 35 and older, n=463) at baseline, 12 months, and 24 months.
- Patients in the 18 to 25 age group tended to have greater brain volume at baseline but more active disease as measured by gadolinium-enhancing MRI lesions. There was also a trend for this age group to experience greater whole brain volume loss at both 12 and 24 months compared with the older groups.
- Patients across all age groups treated with ozanimod lost less cortical grey matter volume than did those treated with interferon beta-1a over 24 months.
- The most common adverse reactions that were higher with ozanimod than with interferon beta-1a were upper respiratory tract infections, urinary tract infections, increases of alanine aminotransferase, and increases of gamma-glutamyl transferase